Three angiostatic peptides, identified through the same methodology and derived from either type IV collagen, CXCL1, or a thrombospondin domain-containing protein were tested in an in vivo MDA-MB-231 breast cancer model [308]. The gene discussed is CXCL1; the disease is breast carcinoma.